X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home IPR Data Management

Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases

Yuvraj_pawp by Yuvraj_pawp
27th November 2017
in IPR Data Management

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 9,820,964 to the Company with claims covering the use of pharmaceutical compositions comprising anabasum for the treatment of multiple fibrotic diseases, including the Company’s lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis as well as others. The patent provides intellectual property protection in the United States for the use of anabasum through 2034. This patent follows the recently issued patent 9,801,849 covering uses of anabasum in multiple inflammatory diseases including systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, psoriasis and others.

This patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the synthesis, manufacturing, formulation and uses of anabasum for a variety of indications including the Company’s lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis and systemic lupus erythematosus. Anabasum is a synthetic oral endocannabinoid-mimetic drug candidate designed to resolve chronic inflammation and fibrosis through the activation of the CB2 receptor to stimulate production of specialized pro-resolving mediators.

Mark Tepper, Ph.D., President and Chief Scientific Officer of Corbus, stated, “The issuance of this specific patent reaffirms the unique properties of anabasum to treat systemic sclerosis, dermatomyositis, cystic fibrosis and other rare fibrotic diseases for which there are limited therapeutic options for patients. This issued patent, along with the Company’s other recently issued U.S. Patent No. 9,801,849 covering the use of anabasum for multiple inflammatory diseases, provides Corbus with broad intellectual property rights to anabasum to 2034.”

Yuval Cohen, Ph.D., CEO of Corbus, stated, “The issuance of this second key patent this year is a reflection of our success in creating and expanding a robust intellectual property portfolio around anabasum.”

About Anabasum
Anabasum is a synthetic oral endocannabinoid-mimetic drug that preferentially binds to cannabinoid receptor type 2 (CB2) expressed on activated immune cells and fibroblasts. CB2 activation triggers physiologic pathways that resolve inflammation, speed bacterial clearance and halt fibrosis. Nonclinical and human clinical studies to date have shown anabasum has favorable safety, tolerability and pharmacokinetic profiles. It has also demonstrated promising potency in nonclinical models of inflammation and fibrosis. Anabasum is designed to trigger the production of “Specialized Pro-resolving Lipid Mediators” that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Anabasum also is designed to have a direct effect on fibroblasts to halt tissue scarring. In effect, anabasum is believed to trigger endogenous pathways to turn “off” chronic inflammation and fibrotic processes without causing immunosuppression.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has generated positive data in Phase 2 studies in diffuse cutaneous systemic sclerosis, cystic fibrosis and dermatomyositis. Additionally, the Company is evaluating anabasum in open-label extension studies in systemic sclerosis and skin-predominant dermatomyositis. The Company expects to commence a Phase 2 study in systemic lupus erythematosus, a Phase 3 study in systemic sclerosis and a Phase 2b study in cystic fibrosis in the fourth quarter of 2017.

For more information, please visit www.CorbusPharma.com

Investor Contact
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: (908) 938-1475
Email: jenene@jenenethomascommunications.com

Media Contact
Nic DiBella
JPA Health Communications
Phone: (617) 657-1307
Email: Nic@jpa.com

Previous Post

Teva Announces New Organization Structure and Leadership Changes

Next Post

Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development

Related Posts

IPR Data Management

OPTIMA Has Made AstraZeneca And Mutabor Official Partners

10th October 2022
Big Data Steering Group To Better Data Effectiveness, Search
IPR Data Management

Big Data Steering Group To Better Data Effectiveness, Search

3rd August 2022
Data For Treatment of Schizophrenia Disclosed By Cyclerion
IPR Data Management

Data For Treatment of Schizophrenia Disclosed By Cyclerion

1st August 2022
Authorities Agree To Work Together Towards Integrating RWE
IPR Data Management

Authorities Agree To Work Together Towards Integrating RWE

1st August 2022
Shimadzu's Nexera XS Inert Chromatography System Enhances Biopharma Analysis
IPR Data Management

Shimadzu’s Nexera XS Inert Chromatography System Enhances Biopharma Analysis

28th July 2022
Eagle Genomics and Quadram Institute's New Strategic Partnership to Accelerate Microbiome Analysis Through AI-Augmented Knowledge Discovery Platform
Drug Development

Eagle Genomics and Quadram Institute’s New Strategic Partnership to Accelerate Microbiome Analysis Through AI-Augmented Knowledge Discovery Platform

13th January 2022
Next Post

Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development

Latest News

Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In